https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-stifel-2026-healthcare-conference BiopharmaWatch en 2026-10-29T17:05:00.000Z Pulse Biosciences to Present at Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-20261029 BiopharmaWatch en 2026-10-29T16:30:00.000Z Perrigo Announces Quarterly Dividend https://www.biopharmawatch.com/news/UTMD/utah-medical-products-corrected-results-tender-offer BiopharmaWatch en 2026-10-29T16:10:00.000Z Utah Medical Products, Inc. Reports Corrected Results of Tender Offer https://www.biopharmawatch.com/news/NRSN/neurosense-primec-phase-3-development-neals-2026 BiopharmaWatch en 2026-10-29T15:30:00.000Z NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 https://www.biopharmawatch.com/news/PFE/edison-scientific-agreement-pfizer-rd BiopharmaWatch en 2026-10-29T15:00:00.000Z Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development https://www.biopharmawatch.com/news/VVOS/correction-sod-sciences-welcomes-vivos-therapeutics-strategic-investor-partner-rebalu BiopharmaWatch en 2026-10-29T14:52:00.000Z CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test https://www.biopharmawatch.com/news/NVAX/novavax-sanofi-phase-3-combination-vaccine-trial BiopharmaWatch en 2026-10-29T13:37:00.000Z Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe https://www.biopharmawatch.com/news/AIDX/2020-biolabs-investor-webinar-november-2026 BiopharmaWatch en 2026-10-29T13:37:00.000Z 20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy https://www.biopharmawatch.com/news/COSM/cosmos-health-us-active-subscriptions-surpass-12000 BiopharmaWatch en 2026-10-29T13:23:00.000Z Cosmos Health's U.S. Active Subscriptions Surpass 12,000, Up 92% in Two Weeks https://www.biopharmawatch.com/news/CODX/co-diagnostics-q3-2026-earnings-release-webcast BiopharmaWatch en 2026-10-29T13:15:00.000Z Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast https://www.biopharmawatch.com/news/INMB/inmune-bio-third-quarter-2026-update BiopharmaWatch en 2026-10-29T13:15:00.000Z INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th https://www.biopharmawatch.com/news/PPBT/purple-biotech-im1240-oral-presentation-eortc-nci-aacr BiopharmaWatch en 2026-10-29T13:00:00.000Z Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/CELU/celularity-vesalius-collaboration-peptual-peptide-apis BiopharmaWatch en 2026-10-29T13:00:00.000Z Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States https://www.biopharmawatch.com/news/ABT/abbott-initiates-crown-mv-trial-cephea-device BiopharmaWatch en 2026-10-29T13:00:00.000Z Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease https://www.biopharmawatch.com/news/CODX/co-diagnostics-cosara-hpv-screening-study-publication BiopharmaWatch en 2026-10-29T13:00:00.000Z Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test https://www.biopharmawatch.com/news/PRGO/perrigo-divests-infant-formula-business-meridianmade BiopharmaWatch en 2026-10-29T13:00:00.000Z Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade https://www.biopharmawatch.com/news/ROIV/roivant-social-ventures-support-no-patient-left-behind BiopharmaWatch en 2026-10-29T13:00:00.000Z Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-phase-2-amplify-7p-results-sitc-2026 BiopharmaWatch en 2026-10-29T13:00:00.000Z Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-art27-13-pain-treatment-presentation BiopharmaWatch en 2026-10-29T13:00:00.000Z Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain https://www.biopharmawatch.com/news/XGN/exagen-inc-participate-investor-conferences BiopharmaWatch en 2026-10-29T13:00:00.000Z Exagen Inc. to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/CADL/candel-therapeutics-aglatimagene-sitc-2026-presentation BiopharmaWatch en 2026-10-29T13:00:00.000Z Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer https://www.biopharmawatch.com/news/IMCR/immunocore-phase-1-data-brenetafusp-kimmtrak-sitc-2026 BiopharmaWatch en 2026-10-29T13:00:00.000Z Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting https://www.biopharmawatch.com/news/BMRN/biomarin-exclusive-license-agreement-gc-biopharma-hanmi BiopharmaWatch en 2026-10-29T12:45:00.000Z BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease https://www.biopharmawatch.com/news/SABS/sab-bio-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-29T12:30:27.000Z SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET https://www.biopharmawatch.com/news/XENE/xen1120-phase-2-ready-kv7-channel-opener BiopharmaWatch en 2026-10-29T12:30:00.000Z XEN1120, a Phase 2-Ready KV7 Channel Opener: Advancing a Novel Non- Opioid Strategy for Pain https://www.biopharmawatch.com/news/XENE/xen1701-phase-2-ready-nav1-7-inhibitor BiopharmaWatch en 2026-10-29T12:30:00.000Z XEN1701, a Phase 2-Ready NaV1.7 Inhibitor: Advancing a Novel Non-Opioid Strategy for Pain https://www.biopharmawatch.com/news/UTMD/utah-medical-products-tender-offer-results BiopharmaWatch en 2026-10-29T12:30:00.000Z Utah Medical Products, Inc. Reports Results of Tender Offer https://www.biopharmawatch.com/news/HCA/hca-healthcare-hospitals-healthgrades-recognition BiopharmaWatch en 2026-10-29T12:30:00.000Z More Than 100 HCA Healthcare Hospitals Recognized by Healthgrades for Excellence in Specialty Care https://www.biopharmawatch.com/news/AZTR/azitra-expands-atr-04-trial-eligibility BiopharmaWatch en 2026-10-29T12:30:00.000Z Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-q3-2026-business-update-call BiopharmaWatch en 2026-10-29T12:30:00.000Z Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026 https://www.biopharmawatch.com/news/XENE/xenon-positive-phase-1-preclinical-data-iasp-2026 BiopharmaWatch en 2026-10-29T12:30:00.000Z Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-virtue-sab-tct-2026-presentation BiopharmaWatch en 2026-10-29T12:30:00.000Z Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026 https://www.biopharmawatch.com/news/CELC/celcuity-q3-2026-results-webcast-call BiopharmaWatch en 2026-10-29T12:30:00.000Z Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-third-quarter-2026-results BiopharmaWatch en 2026-10-29T12:30:00.000Z Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-corporate-update-q3-2026 BiopharmaWatch en 2026-10-29T12:30:00.000Z Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/MLSS/milestone-scientific-growth-update-compuflo-expansion BiopharmaWatch en 2026-10-29T12:30:00.000Z Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-november-investor-events BiopharmaWatch en 2026-10-29T12:30:00.000Z Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data https://www.biopharmawatch.com/news/GH/guardant-health-new-law-colorectal-cancer-screening BiopharmaWatch en 2026-10-29T12:05:00.000Z Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians https://www.biopharmawatch.com/news/RIGL/rigel-conference-call-q3-2026-results BiopharmaWatch en 2026-10-29T12:05:00.000Z Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ACRV/acrivon-phase-1-2-acr-2316-eortc-nci-aacr-symposium BiopharmaWatch en 2026-10-29T12:00:50.000Z Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/RFL/rafael-holdings-fiscal-2026-results-update BiopharmaWatch en 2026-10-29T12:00:00.000Z Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ANVS/annovis-participate-us-biotech-day-pharma-partnering-summit-2026 BiopharmaWatch en 2026-10-29T12:00:00.000Z Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026 https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-early-lung-cancer-detection BiopharmaWatch en 2026-10-29T12:00:00.000Z bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month https://www.biopharmawatch.com/news/TWST/twist-bioscience-launches-mrd-express BiopharmaWatch en 2026-10-29T12:00:00.000Z Twist Bioscience Launches MRD Express with Rapid Turnaround Time https://www.biopharmawatch.com/news/NTRA/natera-third-quarter-results-november-2026 BiopharmaWatch en 2026-10-29T12:00:00.000Z Natera to Report its Third Quarter Results on November 5, 2026 https://www.biopharmawatch.com/news/LCTX/lineage-update-resonance-program-hearing-loss BiopharmaWatch en 2026-10-29T12:00:00.000Z Lineage Provides Update on ReSonance® Program for Hearing Loss https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-q3-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z Establishment Labs® Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ANGO/angiodynamics-participate-investor-conferences BiopharmaWatch en 2026-10-29T12:00:00.000Z AngioDynamics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NVAX/novavax-q3-2026-financial-results-release BiopharmaWatch en 2026-10-29T12:00:00.000Z Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/MRK/merck-manuals-sunscreen-types BiopharmaWatch en 2026-10-29T12:00:00.000Z Merck Manuals Helps Patients Navigate the Different Types of Sunscreens https://www.biopharmawatch.com/news/NUVB/nuvation-bio-sigma-study-expansion-europe BiopharmaWatch en 2026-10-29T12:00:00.000Z Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries https://www.biopharmawatch.com/news/ELOX/eloxx-fda-clearance-exaluren-adpkd-trial BiopharmaWatch en 2026-10-29T12:00:00.000Z Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-q3-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/ECOR/electrocore-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-29T12:00:00.000Z electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/PYPD/polypid-q3-2026-financial-results-report BiopharmaWatch en 2026-10-29T12:00:00.000Z PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026 https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-third-quarter-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights https://www.biopharmawatch.com/news/XAIR/beyond-air-conference-call-financial-results-q3-2026 BiopharmaWatch en 2026-10-29T12:00:00.000Z Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q3-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-publication-results-phase-3-efzo-fit-study BiopharmaWatch en 2026-10-29T12:00:00.000Z aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine https://www.biopharmawatch.com/news/MDWD/mediwound-report-q3-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z MediWound to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q1-fy27 BiopharmaWatch en 2026-10-29T12:00:00.000Z Immutep Quarterly Activities Report Q1 FY27 https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-skny-1-obesity-study-results BiopharmaWatch en 2026-10-29T12:00:00.000Z MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide https://www.biopharmawatch.com/news/NTLA/intellia-lonvoguran-ziclumeran-investor-event-acaa-2026 BiopharmaWatch en 2026-10-29T12:00:00.000Z Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026 https://www.biopharmawatch.com/news/COLL/collegium-boston-legacy-partnership-neurodiversity BiopharmaWatch en 2026-10-29T12:00:00.000Z Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts https://www.biopharmawatch.com/news/SCYX/scynexis-participate-guggenheim-healthcare-conference BiopharmaWatch en 2026-10-29T12:00:00.000Z SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-corporate-pipeline-progress BiopharmaWatch en 2026-10-29T12:00:00.000Z Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics https://www.biopharmawatch.com/news/FEED/envue-medical-uroshield-production-uk-orders BiopharmaWatch en 2026-10-29T11:30:00.000Z ENvue Medical Commences U.S. Production of UroShield(R) and Begins Fulfilling UK Distributor Orders https://www.biopharmawatch.com/news/VRAX/virax-biolabs-distributors-immune-select-china BiopharmaWatch en 2026-10-29T11:30:00.000Z Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-intelligent-orthopedic-surgery-aahks-2026 BiopharmaWatch en 2026-10-29T11:30:00.000Z Zimmer Biomet to Preview the Next Era of Intelligent Orthopedic Surgery at AAHKS 2026 https://www.biopharmawatch.com/news/ADCT/adct-zynlonta-updates-japan BiopharmaWatch en 2026-10-29T11:30:00.000Z ADC Therapeutics Announces ZYNLONTA® Updates in Japan https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-10-29T11:30:00.000Z Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/SIGA/siga-business-update-call-november-2026 BiopharmaWatch en 2026-10-29T11:30:00.000Z SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CNSY/cerenome-completes-enrollment-phase-2-respect-gbm-trial BiopharmaWatch en 2026-10-29T11:30:00.000Z Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma https://www.biopharmawatch.com/news/CRVO/cervomed-announces-publication-two-peer-reviewed-research-articles-supporting-neflamapimod BiopharmaWatch en 2026-10-29T11:30:00.000Z CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB) https://www.biopharmawatch.com/news/DAVI/davion-healthcare-acquires-home-healthcare-business BiopharmaWatch en 2026-10-29T11:30:00.000Z Davion Healthcare PLC Agrees $13.5 Million Acquisition of Profitable US Home Healthcare Business https://www.biopharmawatch.com/news/BAX/baxter-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-29T11:15:00.000Z Baxter Reports Third-Quarter 2026 Results https://www.biopharmawatch.com/news/RGNX/regenxbio-conference-call-november-2026 BiopharmaWatch en 2026-10-29T11:05:00.000Z REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/OCGN/ocugen-participate-november-investor-conferences BiopharmaWatch en 2026-10-29T11:02:00.000Z Ocugen to Participate in Upcoming November Investor and Industry Conferences https://www.biopharmawatch.com/news/STAA/staar-surgical-appoints-pascal-aeschlimann-vp-asia-pacific BiopharmaWatch en 2026-10-29T11:01:00.000Z STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific https://www.biopharmawatch.com/news/DTIL/precision-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-10-29T11:01:00.000Z Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/RFL/rafael-holdings-nda-submission-remibetadex-npc BiopharmaWatch en 2026-10-29T11:00:00.000Z Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-kio-401-crao-naion-trial BiopharmaWatch en 2026-10-29T11:00:00.000Z Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan https://www.biopharmawatch.com/news/EYE/national-vision-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-29T11:00:00.000Z National Vision Holdings, Inc. Announces Third Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/ACB/aurora-cannabis-q2-2027-investor-call BiopharmaWatch en 2026-10-29T11:00:00.000Z Aurora Cannabis to Host Second Quarter 2027 Investor Conference Call https://www.biopharmawatch.com/news/BLCO/bausch-lomb-dry-eye-survey-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education https://www.biopharmawatch.com/news/INCY/incyte-reports-q3-2026-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/NVCR/novocure-q3-2026-financial-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-q3-2026-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CTSO/cytosorbents-q3-2026-financial-results-webcast BiopharmaWatch en 2026-10-29T11:00:00.000Z CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/INSM/insmed-reports-q3-2026-financial-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-guggenheim-conference-2026 BiopharmaWatch en 2026-10-29T11:00:00.000Z Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/INDV/indivior-reports-q3-2026-financial-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Indivior Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-november-conferences-2026 BiopharmaWatch en 2026-10-29T11:00:00.000Z Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences https://www.biopharmawatch.com/news/TLRY/tilray-brands-beverage-transformation-phase BiopharmaWatch en 2026-10-29T11:00:00.000Z Tilray Brands Announces Next Phase of Beverage Transformation https://www.biopharmawatch.com/news/IRD/opus-genetics-appoints-new-executives BiopharmaWatch en 2026-10-29T11:00:00.000Z Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-participation-upcoming-investor-conference-inducement-grant BiopharmaWatch en 2026-10-29T11:00:00.000Z Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q3-2026-results-update BiopharmaWatch en 2026-10-29T11:00:00.000Z Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/IOVA/iova-iov-lun-202-results-precision-til-strategy BiopharmaWatch en 2026-10-29T11:00:00.000Z Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC) https://www.biopharmawatch.com/news/GUTS/fractyl-health-research-patient-interest-weight-maintenance BiopharmaWatch en 2026-10-29T11:00:00.000Z Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-data-orladeyo-navenibart-acaa-2026 BiopharmaWatch en 2026-10-29T11:00:00.000Z BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-expansion-discovery-platform BiopharmaWatch en 2026-10-29T11:00:00.000Z C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders https://www.biopharmawatch.com/news/LGND/ligand-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Ligand Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-participate-2026-jefferies-global-healthcare-conference-london BiopharmaWatch en 2026-10-29T11:00:00.000Z Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-q3-2026-results-kt-579-trial BiopharmaWatch en 2026-10-29T11:00:00.000Z Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-q3-2026-results BiopharmaWatch en 2026-10-29T10:59:00.000Z Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 https://www.biopharmawatch.com/news/BIIB/biogen-new-data-alzheimers-ctad-2026 BiopharmaWatch en 2026-10-29T10:59:00.000Z Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026 https://www.biopharmawatch.com/news/PHVS/pharvaris-acaai-2026-annual-scientific-meeting BiopharmaWatch en 2026-10-29T10:50:00.000Z Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-q3-2026-financial-results BiopharmaWatch en 2026-10-29T10:50:00.000Z Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/LLY/lilly-q3-2026-financial-results-guidance-regulatory-progress BiopharmaWatch en 2026-10-29T10:45:00.000Z Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio https://www.biopharmawatch.com/news/THC/tenet-reports-strong-q3-2026-results BiopharmaWatch en 2026-10-29T10:45:00.000Z Tenet Reports Strong Third Quarter 2026 Results; Raises 2026 Financial Outlook https://www.biopharmawatch.com/news/BFLY/butterfly-network-q3-2026-results BiopharmaWatch en 2026-10-29T10:30:00.000Z Butterfly Network Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MRK/merck-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-29T10:30:00.000Z Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline https://www.biopharmawatch.com/news/HIT/health-in-tech-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-29T10:30:00.000Z Health In Tech to Announce Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/IMUX/immunic-virtual-rd-day-progressive-ms-november-2026 BiopharmaWatch en 2026-10-29T10:30:00.000Z Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026 https://www.biopharmawatch.com/news/FTRE/fortrea-reports-q3-2026-results BiopharmaWatch en 2026-10-29T10:30:00.000Z Fortrea Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/MD/pediatrix-medical-group-reports-third-quarter-results BiopharmaWatch en 2026-10-29T10:00:00.000Z Pediatrix Medical Group Reports Third Quarter Results https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q3-2026-earnings-call BiopharmaWatch en 2026-10-29T10:00:00.000Z Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/WST/west-pharmaceutical-third-quarter-2026-results BiopharmaWatch en 2026-10-29T10:00:00.000Z West Reports Third-Quarter 2026 Results https://www.biopharmawatch.com/news/RDNT/radnet-q3-2026-financial-results-conference-call BiopharmaWatch en 2026-10-29T10:00:00.000Z RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/OCS/oculis-privosegtor-pioneer-program-apois-cns-summit BiopharmaWatch en 2026-10-29T09:10:00.000Z Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit https://www.biopharmawatch.com/news/PHG/philips-uniguide-3d-live-guidance-launch BiopharmaWatch en 2026-10-29T09:00:00.000Z Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform https://www.biopharmawatch.com/news/EVO/evotec-announces-results-november-2026 BiopharmaWatch en 2026-10-29T07:00:00.000Z Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026 https://www.biopharmawatch.com/news/TAK/takeda-fy2026-first-half-results-launch-momentum BiopharmaWatch en 2026-10-29T06:36:00.000Z Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones https://www.biopharmawatch.com/news/MOLN/molecular-partners-q3-2026-financial-results BiopharmaWatch en 2026-10-29T06:00:29.000Z Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy https://www.biopharmawatch.com/news/ADXN/addex-increases-issued-share-capital BiopharmaWatch en 2026-10-29T06:00:00.000Z ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES https://www.biopharmawatch.com/news/MESO/mesoblast-quarterly-report-september-2026 BiopharmaWatch en 2026-10-29T00:19:00.000Z Activity Report for Quarter Ended September 30, 2026 (Appendix 4C) https://www.biopharmawatch.com/news/HCM/hutchmed-sovleplenib-fda-orphan-drug-designation-itp BiopharmaWatch en 2026-10-29T00:00:00.000Z HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia https://www.biopharmawatch.com/news/IOVA/iovance-webcast-positive-data-til-therapy-mnslc BiopharmaWatch en 2026-10-28T23:00:00.000Z Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy https://www.biopharmawatch.com/news/PRPO/precipio-q3-2026-shareholder-update-call BiopharmaWatch en 2026-10-28T21:00:00.000Z Precipio Announces Q3-2026 Shareholder Update Call https://www.biopharmawatch.com/news/DBVT/dbv-technologies-q3-2026-financial-results BiopharmaWatch en 2026-10-28T20:47:00.000Z DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/QTRX/quanterix-third-quarter-2026-results-call BiopharmaWatch en 2026-10-28T20:30:00.000Z Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-webcast-first-quarter-results BiopharmaWatch en 2026-10-28T20:30:00.000Z Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-strategic-process-ttx-mc138 BiopharmaWatch en 2026-10-28T20:30:00.000Z TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio https://www.biopharmawatch.com/news/AMGN/amgen-webcast-2026-q3-financial-results BiopharmaWatch en 2026-10-28T20:30:00.000Z AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS https://www.biopharmawatch.com/news/STE/steris-announces-dividend-0-69-per-share BiopharmaWatch en 2026-10-28T20:30:00.000Z STERIS Announces Dividend of $0.69 per share https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-q3-2026-results-reorganization-ceo-transition BiopharmaWatch en 2026-10-28T20:30:00.000Z LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession https://www.biopharmawatch.com/news/EHC/encompass-health-q3-2026-results BiopharmaWatch en 2026-10-28T20:24:25.943Z Encompass Health reports results for third quarter 2026 https://www.biopharmawatch.com/news/CYH/community-health-systems-q3-2026-results BiopharmaWatch en 2026-10-28T20:15:00.000Z Community Health Systems, Inc. Announces Third Quarter Ended September 30, 2026 Results https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inducement-grants-october-2026 BiopharmaWatch en 2026-10-28T20:15:00.000Z Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q3-2026-results-announcement BiopharmaWatch en 2026-10-28T20:12:00.000Z Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 https://www.biopharmawatch.com/news/AORT/artivion-participate-upcoming-investor-conferences-20261028 BiopharmaWatch en 2026-10-28T20:10:00.000Z Artivion to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BHC/bausch-health-redemption-senior-notes-2027 BiopharmaWatch en 2026-10-28T20:07:00.000Z Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027 https://www.biopharmawatch.com/news/BHC/bausch-health-announces-share-repurchase-program BiopharmaWatch en 2026-10-28T20:06:00.000Z Bausch Health Announces US$50 Million Share Repurchase Program https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-q3-2026-results BiopharmaWatch en 2026-10-28T20:05:00.000Z ClearPoint Neuro Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/ALGN/align-technology-ceo-succession-plan BiopharmaWatch en 2026-10-28T20:05:00.000Z Align Technology Announces CEO Succession Plan https://www.biopharmawatch.com/news/CNMD/conmed-reports-q3-2026-results-guidance-update BiopharmaWatch en 2026-10-28T20:05:00.000Z CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance https://www.biopharmawatch.com/news/ALGN/align-technology-q3-2026-financial-results BiopharmaWatch en 2026-10-28T20:05:00.000Z Align Technology Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GKOS/glaukos-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-28T20:05:00.000Z Glaukos Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-third-quarter-2026-update BiopharmaWatch en 2026-10-28T20:05:00.000Z Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-ubs-global-biopharma-conference-2026 BiopharmaWatch en 2026-10-28T20:05:00.000Z Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026 https://www.biopharmawatch.com/news/NEO/neogenomics-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-28T20:05:00.000Z NeoGenomics Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/CHRS/coherus-tagmokitug-esophageal-cancer-data BiopharmaWatch en 2026-10-28T20:05:00.000Z Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development https://www.biopharmawatch.com/news/CBLL/ceribell-participate-canaccord-genuity-medtech-diagnostics-digital-health-services-forum BiopharmaWatch en 2026-10-28T20:05:00.000Z Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-kol-event-nf1-treatment BiopharmaWatch en 2026-10-28T20:05:00.000Z Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026 https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q3-2026-results-conference-call BiopharmaWatch en 2026-10-28T20:05:00.000Z Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-10-28T20:05:00.000Z Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/PGEN/precigen-announces-q3-2026-results-call BiopharmaWatch en 2026-10-28T20:05:00.000Z Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4 https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-q3-2026-results BiopharmaWatch en 2026-10-28T20:05:00.000Z Teladoc Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/MDXG/mimedx-third-quarter-2026-results BiopharmaWatch en 2026-10-28T20:03:00.000Z MIMEDX Announces Third Quarter 2026 Operating & Financial Results https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-name-change-azora-therapeutics BiopharmaWatch en 2026-10-28T20:02:00.000Z Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-10-28T20:01:00.000Z Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-579-phase-1-results BiopharmaWatch en 2026-10-28T20:01:00.000Z Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026 https://www.biopharmawatch.com/news/MDXG/mimedx-patent-license-agreement-25-million BiopharmaWatch en 2026-10-28T20:01:00.000Z MIMEDX Announces $25 Million Patent License Agreement https://www.biopharmawatch.com/news/SPRY/ars-pharma-third-quarter-2026-results BiopharmaWatch en 2026-10-28T20:01:00.000Z ARS Pharma to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MLAB/mesa-labs-second-quarter-results-2026 BiopharmaWatch en 2026-10-28T20:00:00.000Z Mesa Labs Announces Second Quarter Financial Results Release Date and Earnings Conference Call https://www.biopharmawatch.com/news/LLY/lilly-licenses-speechdx-dataset-alzheimers-research BiopharmaWatch en 2026-10-28T15:43:00.000Z Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator Licenses SpeechDx Dataset to Eli Lilly and Company, Advancing Speech-Based Markers as a Critical Alzheimer's Research Tool https://www.biopharmawatch.com/news/GMAB/genmab-petosemtamab-head-neck-cancer-trial-results BiopharmaWatch en 2026-10-28T13:40:00.000Z Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer https://www.biopharmawatch.com/news/COSM/noble-capital-markets-initiates-coverage-cosmos-health BiopharmaWatch en 2026-10-28T13:20:00.000Z Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target https://www.biopharmawatch.com/news/OSRH/osr-health-shareholder-update-nasdaq-decision BiopharmaWatch en 2026-10-28T13:15:00.000Z OSR Health Provides Shareholder Update Following Nasdaq Panel Decision https://www.biopharmawatch.com/news/LGVN/longeveron-engages-lucid-capital-markets BiopharmaWatch en 2026-10-28T13:15:00.000Z Longeveron Announces Engagement of Lucid Capital Markets https://www.biopharmawatch.com/news/LEXX/lexaria-celebrates-70th-patent-award BiopharmaWatch en 2026-10-28T13:12:55.000Z Lexaria Celebrates its 70th Patent Award https://www.biopharmawatch.com/news/ARQT/arcutis-appoints-rob-scott-board-directors BiopharmaWatch en 2026-10-28T13:00:24.000Z Arcutis Appoints Rob Scott, MD to Board of Directors https://www.biopharmawatch.com/news/ARQT/arcutis-appoints-rob-scott-to-board BiopharmaWatch en 2026-10-28T13:00:24.000Z Arcutis Appoints Rob Scott, MD to Board of Directors https://www.biopharmawatch.com/news/ILMN/illuminate-rx-expands-affordability-sempre-health-partnership BiopharmaWatch en 2026-10-28T13:00:00.000Z Illuminate Rx Expands Member Affordability Through Sempre Health Partnership https://www.biopharmawatch.com/news/OPK/opko-health-q3-2026-results-report BiopharmaWatch en 2026-10-28T12:52:00.000Z OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/DARE/dare-bioscience-womens-health-focus-investor-discussion BiopharmaWatch en 2026-10-28T12:47:00.000Z Daré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-phase-3-regal-trial-update BiopharmaWatch en 2026-10-28T12:35:00.000Z SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia https://www.biopharmawatch.com/news/PALI/palisade-bio-first-patient-dosed-ascentra-uc-study BiopharmaWatch en 2026-10-28T12:32:00.000Z Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis https://www.biopharmawatch.com/news/BEAT/heartbeam-align-acs-study-results-tct-2026 BiopharmaWatch en 2026-10-28T12:31:00.000Z HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026 https://www.biopharmawatch.com/news/MTVA/metavia-phase-1-trial-data-presentation-precision-liver-symposium BiopharmaWatch en 2026-10-28T12:31:00.000Z MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026 https://www.biopharmawatch.com/news/NMAD/nomad-expands-utility-sales-network-26-states BiopharmaWatch en 2026-10-28T12:30:00.000Z NOMAD Expands Utility Sales Network to 26 States with Two Representative Agreements https://www.biopharmawatch.com/news/COCH/envoy-medical-q3-2026-earnings-call-update BiopharmaWatch en 2026-10-28T12:30:00.000Z Envoy Medical Updates Third Quarter 2026 Earnings Call Time to 8:00 A.M. ET on Thursday, November 5th https://www.biopharmawatch.com/news/SUPN/chloe-kim-ms-represented-campaign-adhd BiopharmaWatch en 2026-10-28T12:30:00.000Z Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign https://www.biopharmawatch.com/news/VIR/vir-biotechnology-suzanne-topalian-appointment BiopharmaWatch en 2026-10-28T12:30:00.000Z Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors https://www.biopharmawatch.com/news/SDGR/schrodinger-presents-ubs-global-healthcare-conference BiopharmaWatch en 2026-10-28T12:30:00.000Z Schrödinger to Present at UBS Global Healthcare Conference https://www.biopharmawatch.com/news/EOLS/evolus-investor-conferences-new-york-london BiopharmaWatch en 2026-10-28T12:30:00.000Z Evolus to Participate in Upcoming Investor Conferences in New York and London https://www.biopharmawatch.com/news/EVGN/evogene-aGVHD-ai-drug-discovery-program BiopharmaWatch en 2026-10-28T12:30:00.000Z Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2026-q3-financial-results BiopharmaWatch en 2026-10-28T12:30:00.000Z Spectral AI Schedules 2026 Third Quarter Financial Results and Conference Call https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-partnership-usm-alpha-gal-syndrome BiopharmaWatch en 2026-10-28T12:30:00.000Z 60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-phase-1b-study-advanced-cancer BiopharmaWatch en 2026-10-28T12:30:00.000Z Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-appoints-neera-clase-cco BiopharmaWatch en 2026-10-28T12:30:00.000Z Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer https://www.biopharmawatch.com/news/RNXT/renovorx-participate-canaccord-genuity-forum BiopharmaWatch en 2026-10-28T12:30:00.000Z RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum https://www.biopharmawatch.com/news/MXCT/maxcyte-participate-investor-conferences-2026 BiopharmaWatch en 2026-10-28T12:05:00.000Z MaxCyte to Participate in Three Upcoming Investor Conferences https://www.biopharmawatch.com/news/URGN/urogen-olympus-five-year-study-results-jelmyto BiopharmaWatch en 2026-10-28T12:00:00.000Z UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer https://www.biopharmawatch.com/news/WAT/waters-ai-powered-peak-integration-empower-software BiopharmaWatch en 2026-10-28T12:00:00.000Z Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software https://www.biopharmawatch.com/news/DXCM/dexcom-g7-launch-canada-november BiopharmaWatch en 2026-10-28T12:00:00.000Z Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November https://www.biopharmawatch.com/news/TWST/twist-bioscience-launches-express-screening-antibodies BiopharmaWatch en 2026-10-28T12:00:00.000Z Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies https://www.biopharmawatch.com/news/AZN/astrazeneca-mark-paul-gosselaar-meet-your-mark-campaign BiopharmaWatch en 2026-10-28T12:00:00.000Z AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing https://www.biopharmawatch.com/news/COYA/coya-therapeutics-nfl-biomarker-stratification-neals-2026 BiopharmaWatch en 2026-10-28T12:00:00.000Z Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting https://www.biopharmawatch.com/news/PYPD/polypid-expands-pipeline-introduces-pd01b BiopharmaWatch en 2026-10-28T12:00:00.000Z PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections https://www.biopharmawatch.com/news/ENLV/enlivex-announces-randomization-135-patients-phase-2b-trial-allocetra-age BiopharmaWatch en 2026-10-28T12:00:00.000Z Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis https://www.biopharmawatch.com/news/IMMP/immutep-receives-a2-16-million-french-tax-incentive BiopharmaWatch en 2026-10-28T12:00:00.000Z Immutep Receives A$2.16 million French R&D Tax Incentive https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-simufilam-preclinical-findings BiopharmaWatch en 2026-10-28T12:00:00.000Z Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells https://www.biopharmawatch.com/news/ECOR/electrocore-quell-fda-clearance-cipn BiopharmaWatch en 2026-10-28T12:00:00.000Z electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN) https://www.biopharmawatch.com/news/ANNX/annexon-virtual-investor-event-archer-ii-trial BiopharmaWatch en 2026-10-28T12:00:00.000Z Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-4-5-million-offering BiopharmaWatch en 2026-10-28T12:00:00.000Z INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement https://www.biopharmawatch.com/news/GERN/geron-phase-3-impactmf-trial-update BiopharmaWatch en 2026-10-28T12:00:00.000Z Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis https://www.biopharmawatch.com/news/HUMA/humacyte-us-patent-symvess-bioengineered-tissues BiopharmaWatch en 2026-10-28T12:00:00.000Z Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues https://www.biopharmawatch.com/news/PRQR/proqr-present-clinical-preclinical-progress-ax-0810-ax-0811 BiopharmaWatch en 2026-10-28T12:00:00.000Z ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences https://www.biopharmawatch.com/news/BWAY/brainsway-q3-2026-financial-results-report BiopharmaWatch en 2026-10-28T12:00:00.000Z BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-positive-results-bb-301 BiopharmaWatch en 2026-10-28T12:00:00.000Z Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 https://www.biopharmawatch.com/news/VBIO/valion-bio-entolimod-safety-results-therapeutic-study BiopharmaWatch en 2026-10-28T11:45:00.000Z Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation https://www.biopharmawatch.com/news/SIGA/siga-contract-15-million-canadian-defence BiopharmaWatch en 2026-10-28T11:30:00.000Z SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX® https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-investor-conferences-2026 BiopharmaWatch en 2026-10-28T11:30:00.000Z Pyxis Oncology to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PVLA/palvella-fda-acceptance-priority-review-qtorin-rapamycin BiopharmaWatch en 2026-10-28T11:30:00.000Z Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set https://www.biopharmawatch.com/news/MLYS/mineralys-phase-2-explore-ckd-trial-results BiopharmaWatch en 2026-10-28T11:05:00.000Z Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International https://www.biopharmawatch.com/news/QURE/uniqure-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-28T11:05:00.000Z uniQure to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AXGN/axogen-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-28T11:02:00.000Z Axogen, Inc. Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/UTHR/united-therapeutics-fda-clearance-treprostinil-iloprost BiopharmaWatch en 2026-10-28T11:00:00.000Z United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-stifel-2026-healthcare-conference BiopharmaWatch en 2026-10-28T11:00:00.000Z Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-ceo-retirement-announcement BiopharmaWatch en 2026-10-28T11:00:00.000Z Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership https://www.biopharmawatch.com/news/NVCR/novocure-evaluate-ttfields-therapy-vs7375-pancreatic-cancer BiopharmaWatch en 2026-10-28T11:00:00.000Z Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement https://www.biopharmawatch.com/news/CSTL/castle-biosciences-participate-upcoming-investor-conferences BiopharmaWatch en 2026-10-28T11:00:00.000Z Castle Biosciences to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/GNPX/genprex-tusc2-research-gsa-2026-meharry BiopharmaWatch en 2026-10-28T11:00:00.000Z Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting https://www.biopharmawatch.com/news/HCSG/creek-equity-healthcare-services-portfolio BiopharmaWatch en 2026-10-28T11:00:00.000Z Scott Zack's Creek Equity Details Healthcare Services Portfolio Spanning Supply Chain, Pharmacy Benefits, and Medical Courier Logistics https://www.biopharmawatch.com/news/ADAG/adagene-first-patient-phase-1-muzastotug BiopharmaWatch en 2026-10-28T11:00:00.000Z Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-host-person-kol-event-discuss-roluperidone-negative-symptoms BiopharmaWatch en 2026-10-28T11:00:00.000Z Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia https://www.biopharmawatch.com/news/AMRN/amarin-reports-positive-net-income-q3-2026 BiopharmaWatch en 2026-10-28T11:00:00.000Z Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-second-quarter-2027-financial-results-provides-corporate BiopharmaWatch en 2026-10-28T11:00:00.000Z Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-q3-2026-earnings-call BiopharmaWatch en 2026-10-28T11:00:00.000Z Lumexa Imaging Announces Third Quarter 2026 Earnings Conference Call Date https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-appoints-chuck-silberstein-cfo BiopharmaWatch en 2026-10-28T11:00:00.000Z NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer https://www.biopharmawatch.com/news/GLUE/monte-rosa-phase-2-study-mrt-6160-psoriatic-arthritis BiopharmaWatch en 2026-10-28T11:00:00.000Z Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) https://www.biopharmawatch.com/news/ADMA/adma-biologics-q3-2026-financial-results BiopharmaWatch en 2026-10-28T11:00:00.000Z ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-november-2026 BiopharmaWatch en 2026-10-28T11:00:00.000Z Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026 https://www.biopharmawatch.com/news/BLCO/bausch-lomb-third-quarter-performance-2026 BiopharmaWatch en 2026-10-28T10:58:00.000Z Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance https://www.biopharmawatch.com/news/LH/labcorp-reports-strong-2026-q3-results BiopharmaWatch en 2026-10-28T10:54:22.476Z Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance https://www.biopharmawatch.com/news/BDX/bd-liverty-tips-stent-graft-launch BiopharmaWatch en 2026-10-28T10:50:00.000Z BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options https://www.biopharmawatch.com/news/LLY/lilly-retatrutide-a1c-reduction-weight-loss-ozempic BiopharmaWatch en 2026-10-28T10:45:00.000Z Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial https://www.biopharmawatch.com/news/CMPS/compass-pathways-neuroscience-education-congress-2026 BiopharmaWatch en 2026-10-28T10:30:00.000Z Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress https://www.biopharmawatch.com/news/BSX/boston-scientific-q3-2026-results BiopharmaWatch en 2026-10-28T10:30:00.000Z Boston Scientific announces results for third quarter 2026 https://www.biopharmawatch.com/news/GEHC/ge-healthcare-q3-2026-financial-results BiopharmaWatch en 2026-10-28T10:20:00.000Z GE HealthCare reports third quarter 2026 financial results https://www.biopharmawatch.com/news/AVTR/avantor-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-28T10:09:10.092Z Avantor® Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/BIIB/biogen-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-28T10:00:00.000Z Biogen Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/RAPP/rapport-pricing-underwritten-offerings-common-stock-notes BiopharmaWatch en 2026-10-28T10:00:00.000Z Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement https://www.biopharmawatch.com/news/TMO/thermo-fisher-junior-innovators-challenge-2026 BiopharmaWatch en 2026-10-28T02:37:00.000Z 15-year-old Designs Low-Cost Device to Monitor Airborne Bacteria in the Environment; Wins $25,000 Top Award at the 2026 Thermo Fisher Scientific Junior Innovators Challenge https://www.biopharmawatch.com/news/EHTH/health-insurance-open-enrollment-survey-stress BiopharmaWatch en 2026-10-28T00:00:00.000Z Health Insurance Open Enrollment Survey: 57% of Americans Say Picking a Health Plan Is Stressful https://www.biopharmawatch.com/news/BHC/bausch-health-q3-2026-results-guidance-raise BiopharmaWatch en 2026-10-28T00:00:00.000Z BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE https://www.biopharmawatch.com/news/AMGN/amgen-announces-2026-fourth-quarter-dividend BiopharmaWatch en 2026-10-27T22:27:00.000Z AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND https://www.biopharmawatch.com/news/ZURA/zura-bio-inducement-grants-nasdaq BiopharmaWatch en 2026-10-27T22:00:00.000Z Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-q3-financial-results-2026 BiopharmaWatch en 2026-10-27T22:00:00.000Z Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets https://www.biopharmawatch.com/news/IVF/invo-fertility-reverse-stock-split-october-2026 BiopharmaWatch en 2026-10-27T22:00:00.000Z INVO Fertility Announces a 1:4 Reverse Stock Split Effective Pre-Market Opening on October 30, 2026 https://www.biopharmawatch.com/news/URGN/urogen-pharma-third-quarter-2026-results BiopharmaWatch en 2026-10-27T22:00:00.000Z UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026 https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-27T20:43:00.000Z ICON Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/NVST/envista-2025-sustainability-report BiopharmaWatch en 2026-10-27T20:34:00.000Z Envista Announces Release of 2025 Sustainability Report https://www.biopharmawatch.com/news/RAPP/rapport-announces-public-offerings-concurrent-private-placement BiopharmaWatch en 2026-10-27T20:32:00.000Z Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement https://www.biopharmawatch.com/news/DBVT/dbv-technologies-third-quarter-2026-results BiopharmaWatch en 2026-10-27T20:30:00.000Z DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 https://www.biopharmawatch.com/news/CARL/carlsmed-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-27T20:30:00.000Z Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/PACS/pacs-group-third-quarter-2026-earnings-release BiopharmaWatch en 2026-10-27T20:22:00.000Z PACS Group Schedules Third Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/UHS/universal-health-services-financial-results-september-2026 BiopharmaWatch en 2026-10-27T20:16:27.000Z Universal Health Services, Inc. Announces Financial Results for the Three and Nine-Month Periods Ended September 30, 2026 https://www.biopharmawatch.com/news/ILMN/illumina-webcast-investor-conference-november-2026 BiopharmaWatch en 2026-10-27T20:15:00.000Z Illumina To Webcast Upcoming Investor Conference https://www.biopharmawatch.com/news/PETS/petmed-express-q2-fiscal-year-2027-results BiopharmaWatch en 2026-10-27T20:15:00.000Z PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026 https://www.biopharmawatch.com/news/CHE/chemed-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-27T20:15:00.000Z Chemed Reports Third-Quarter 2026 Results https://www.biopharmawatch.com/news/ENSG/ensign-group-q3-2026-results-guidance BiopharmaWatch en 2026-10-27T20:08:00.000Z The Ensign Group Reports Third Quarter 2026 Results; Raises 2026 Annual Earnings Guidance https://www.biopharmawatch.com/news/ELMD/electromed-q1-fiscal-2027-results-report BiopharmaWatch en 2026-10-27T20:07:00.000Z Electromed, Inc. to Report Q1 Fiscal 2027 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-third-quarter-results-update BiopharmaWatch en 2026-10-27T20:05:00.000Z Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call https://www.biopharmawatch.com/news/BNGO/bionano-report-q3-2026-results-webcast BiopharmaWatch en 2026-10-27T20:05:00.000Z Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026 https://www.biopharmawatch.com/news/RARE/ultragenyx-conference-call-q3-2026 BiopharmaWatch en 2026-10-27T20:05:00.000Z Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-appoints-leila-alland-cmo BiopharmaWatch en 2026-10-27T20:05:00.000Z Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer https://www.biopharmawatch.com/news/ANL/adlai-nortye-an4035-update-eortc-nci-aacr-symposium BiopharmaWatch en 2026-10-27T20:05:00.000Z Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/KIDS/orthopediatrics-fda-clearance-pnp-retrograde-nail-system BiopharmaWatch en 2026-10-27T20:05:00.000Z OrthoPediatrics Announces FDA 510(k) Clearance of PNP | Femur Retrograde Nail System and Completes First Implantations https://www.biopharmawatch.com/news/TELA/tela-bio-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-27T20:05:00.000Z TELA Bio to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SI/shoulder-innovations-investor-conferences BiopharmaWatch en 2026-10-27T20:05:00.000Z Shoulder Innovations to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/TXG/10x-genomics-2026-jefferies-global-healthcare-conference BiopharmaWatch en 2026-10-27T20:05:00.000Z 10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-third-quarter-2026-financial-results-increases-2026 BiopharmaWatch en 2026-10-27T20:05:00.000Z OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance https://www.biopharmawatch.com/news/PACB/pacbio-participate-upcoming-investor-conferences BiopharmaWatch en 2026-10-27T20:05:00.000Z PacBio to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/RVMD/revolution-medicines-investor-conferences-november-2026 BiopharmaWatch en 2026-10-27T20:05:00.000Z Revolution Medicines to Participate in November 2026 Investor Conferences https://www.biopharmawatch.com/news/OM/outset-medical-2026-stifel-healthcare-conference BiopharmaWatch en 2026-10-27T20:05:00.000Z Outset Medical to Participate in the 2026 Stifel Healthcare Conference https://www.biopharmawatch.com/news/LLY/patrik-jonsson-retirement-ilya-yuffa-president-lilly-global-markets BiopharmaWatch en 2026-10-27T20:03:00.000Z Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets https://www.biopharmawatch.com/news/BBNX/beta-bionics-q3-2026-financial-results BiopharmaWatch en 2026-10-27T20:02:00.000Z Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance https://www.biopharmawatch.com/news/GRAL/grail-presents-ubs-global-healthcare-conference BiopharmaWatch en 2026-10-27T20:02:00.000Z GRAIL to Present at the UBS Global Healthcare Conference https://www.biopharmawatch.com/news/LGND/ligand-participate-november-investor-conferences-20261027 BiopharmaWatch en 2026-10-27T20:01:00.000Z Ligand to Participate in November Investor Conferences https://www.biopharmawatch.com/news/STAA/staar-surgical-investor-conferences-november-2026 BiopharmaWatch en 2026-10-27T20:01:00.000Z STAAR Surgical to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-third-quarter-2026-results BiopharmaWatch en 2026-10-27T20:01:00.000Z Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026 https://www.biopharmawatch.com/news/COGT/cogent-biosciences-guggenheim-conference-participation BiopharmaWatch en 2026-10-27T20:01:00.000Z Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-q3-2026-results-investor-day BiopharmaWatch en 2026-10-27T20:01:00.000Z Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation https://www.biopharmawatch.com/news/ARVN/arvinas-early-career-researcher-award-2026 BiopharmaWatch en 2026-10-27T20:01:00.000Z Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation https://www.biopharmawatch.com/news/NRC/nrc-health-q3-2026-results BiopharmaWatch en 2026-10-27T20:00:00.000Z NRC Health Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/AMGN/amgen-new-data-acr-convergence-2026 BiopharmaWatch en 2026-10-27T20:00:00.000Z AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 https://www.biopharmawatch.com/news/ARQT/arcutis-presentation-guggenheim-healthcare-conference BiopharmaWatch en 2026-10-27T20:00:00.000Z Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/AZN/breast-cancer-canada-astrazeneca-survivorship-research BiopharmaWatch en 2026-10-27T18:40:00.000Z Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research